Clinical trial NCT03953014: Pharmacogenetics of Antidepressant-Induced Disinhibition
Official title: Pharmacogenetics of Antidepressant-Induced Disinhibition in Children Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obsessive-Compulsive Disorder
Anxiety Disorders
Major Depressive Disorder
Antidepressant Drug Adverse Reaction
Keywords: SSRI
Depression
Children
OCD
Anxiety
Antidepressants
Lead sponsor: University of Calgary
Sponsor class: OTHER
Collaborators: name: Hotchkiss Brain Institute, University of Calgary
name: Alberta Health services
First posted: 2019-05-16
Enrollment: 120
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: SSRI-treated children diagnosed with major depression, anxiety and OCD, aged 6 to 24 years recruited from the Child and Adolescent Addiction, Mental Health \& Psychiatry (CAAMP) Program in Calgary.

Brief summary: The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

Detailed description: Background and Rationale:

Antidepressants such as serotonin-selective reuptake inhibitors (SSRIs) are frequently prescribed to children to manage major depressive and anxiety disorders. Although SSRIs are thought to be generally effective and well-tolerated in children, 10%- 20% of children treated with SSRIs experience behavioral disinhibition (i.e. activation, hyperactivity, impulsivity, insomnia) that can lead to devastating consequences (e.g. suicidal impulses, violence). There are currently no tools available to assist healthcare providers in predicting which children will experience behavioral disinhibition as a result of SSRI treatment.

Research Question:

Do children who experience SSRI-induced behavioral disinhibition (SIBD) have a distinct pharmacogenetic profile relative to children who do not have these adverse experiences?

Methodology:

Using a retrospective cohort study design, 120 SSRI-treated children diagnose with major depression, anxiety and OCD, aged 6 to 17 years of aged will be recruited from Child and Adolescent Addiction, Mental Health \& Psychiatry (CAAMHP) Program in Calgary. Children with a current or past history of SSRI use will be identified via recruitment advertisements and by CAAMHP treatment teams operating within community clinics as well as inpatient units within the Alberta Children's Hospital and Foothills Medical Centre.

Clinical data will be collected from the participant's medical record as well as information provided by the child's healthcare provider and caretaker using a customized data collection form. Saliva will be collected, processed and genotyped in accordance with standard procedures. Participants and their parents will complete self-report measures to gather information regarding demographics, SIBD, and other adverse side effects and drug reactions.

Using machine learning (i.e. the construction of algorithms that can learn from and make predictions on data) we will identify and validate a panel of genetic variants that could be used to pre-emptively detect children at-risk for developing SSRI-induced behavioral disinhibition.

Eligibility criteria: Inclusion Criteria:

1. Aged 6 - 24 years
2. Medical records available
3. Diagnosis of MDD, anxiety disorder, or OCD
4. Current or past history of SSRI therapy

Exclusion Criteria:

1. Inability of parent/legal guardian to give informed consent
2. Inability of the child to give informed assent
3. Unwillingness of child to provide saliva sample for genetic analysis
4. Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.

Primary outcomes:
measure: Genetic variants in SSRI metabolism
timeFrame: 4 years
measure: Behavioural Disinhibition
timeFrame: 4 years
Secondary outcomes:
measure: Adverse Drug Reactions other than SIBD
timeFrame: 4 years
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Child and Adolescent Addiction, Mental Health & Psychiatry
state: Alberta
Study officials:
affiliation: University of Calgary
name: Chad Bousman, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Calgary
name: Paul Arnold, MD
role: PRINCIPAL_INVESTIGATOR
References: